Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Predictors of response to erenumab after 12 months of treatment.

< BACK TO ARCHIVE


Papers: 17 Jul 2021 - 23 Jul 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Jul 16


Brain Behav


http://www.ncbi.nlm.nih.gov/pubmed/34268907?dopt=Abstract

Predictors of response to erenumab after 12 months of treatment.

Authors

Predictors of response to erenumab after 12 months of treatment.
Baraldi C, Lo Castro F, Cainazzo M M, Pani L, Guerzoni S
Brain Behav. 2021 Jul 16.
PMID: 34268907.

Abstract

Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine. The aim of the present study is to identify clinical predictors of good response in patients with chronic migraine and medication overuse-headache.
Read This Paper